A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study, the first clinical trial of JI-101, is to determine the maximum
tolerated dose of JI-101 when given orally to patients with solid tumors. Safety,
tolerability, pharmacokinetics, pharmacodynamics, and the effects of the drug on tumor
metabolism will also be studied. JI-101 is an inhibitor of new blood vessel growth that may
provide benefit to patients with solid tumors that have failed standard therapeutic regimens.